CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
Dr Daniel Renouf is the pancreatic cancer disease site chair and in this interview he discusses the PA7 trail which explores whether adding immunotherapy to chemotherapy can improve the efficacy or the positive effects of treatment for patients
HN10, A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma, is centrally activated.
Seymour L, Le Teuff G, Brambilla E, Shepherd FA, Soria JC, Kratzke R, Graziano S, Douillard JY, Rosell R, Reiman A, Lacas B, Lueza B, viel-Ronen S, McLeer A, Le Chevalier T, Pirker R, Filipits M, Dunant A, Pignon JP, Tsao MS.
600 PATIENTS RANDOMIZED!!!
Congratulations to Dr. Willibald Schroeder and the team at GYNAEKOLOGICUM Bremen, Germany for enrolling the 600th patient to the SHAPE study! On behalf of the SHAPE trial committee, we would like to thank you for your tremendous and unwavering support of our trial. The countdown is on....let's see the SHAPE trial reach its accrual goal by the end of 2019!
The Supportive Care Committee and Lung Disease Site are actively seeking a CRA representative volunteer from our Canadian centres.
A Canadian Cancer Trials Group update regarding the Protection of Human Research Participant Training
In September 2018, the NIH Office of Extramural Research (OER) released that the current free Protecting Human Research Participant (PHRP) training course would no longer be offered and neither would an alternative. In alignment with the NIH, CCTG confirmed that the CITI Human Subjects Research Course is an acceptable option for Human Subjects Protection training as well as training courses developed and administered at the institutional level.
The CCTG Annual Spring Meeting of Participants is almost here, if you are planning meetings and/or attending the Spring Meeting please read the information below:
